Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Intec Pharma Ltd is a biotechnology business based in the US. Intec Pharma shares (NTEC) are listed on the NASDAQ and all prices are listed in US Dollars. Intec Pharma employs 36 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$3.77|
|52-week range||$8.80 - $36.88|
|50-day moving average||$14.04|
|200-day moving average||$16.63|
|Wall St. target price||$13.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||10.88%|
|3 months (2021-04-30)||-6.91%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-45.7%|
|Return on equity TTM||-113.34%|
|Market capitalisation||$20.1 million|
TTM: trailing 12 months
There are currently 755,321 Intec Pharma shares held short by investors – that's known as Intec Pharma's "short interest". This figure is 42.8% up from 528,997 last month.
There are a few different ways that this level of interest in shorting Intec Pharma shares can be evaluated.
Intec Pharma's "short interest ratio" (SIR) is the quantity of Intec Pharma shares currently shorted divided by the average quantity of Intec Pharma shares traded daily (recently around 1.8 million). Intec Pharma's SIR currently stands at 0.43. In other words for every 100,000 Intec Pharma shares traded daily on the market, roughly 430 shares are currently held short.
However Intec Pharma's short interest can also be evaluated against the total number of Intec Pharma shares, or, against the total number of tradable Intec Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intec Pharma's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Intec Pharma shares in existence, roughly 160 shares are currently held short) or 0.161% of the tradable shares (for every 100,000 tradable Intec Pharma shares, roughly 161 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intec Pharma.
Find out more about how you can short Intec Pharma stock.
We're not expecting Intec Pharma to pay a dividend over the next 12 months.
Intec Pharma's shares were split on a 1:4 basis on 26 July 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intec Pharma shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intec Pharma shares which in turn could have impacted Intec Pharma's share price.
Over the last 12 months, Intec Pharma's shares have ranged in value from as little as $8.8 up to $36.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intec Pharma's is 1.1398. This would suggest that Intec Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.